Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High Following Earnings Beat

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)’s stock price reached a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $33.43 and last traded at $32.5270, with a volume of 2202319 shares changing hands. The stock had previously closed at $33.21.

The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 48.20%. Teva Pharmaceutical Industries’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period last year, the firm posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results materially beat expectations — EPS $0.96 vs. $0.65 consensus and revenue $4.71B vs. $4.36B; management highlighted branded-drug strength (notably Austedo) and a Sanofi milestone that lifted the quarter. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Fourth-quarter profit/revenue rise story notes the milestone payment that kicked off a late‑stage IBD study and helped drive results — supports the case for durable branded-product growth. Teva Pharmaceutical profit, revenue rise in fourth quarter
• Positive Sentiment: Analysts raised targets: Truist bumped its target to $38 (buy) and Scotiabank to $40 (sector outperform), signaling dealer confidence in upside from the beat and pipeline progress. Benzinga TickerReport — Scotiabank target raise
• Positive Sentiment: Company highlights 3rd consecutive year of growth (2025 revenues $17.3B) and positions its pipeline as value‑creating, which supports a longer‑term growth narrative beyond near‑term guidance. GlobeNewswire — Teva delivers 3 consecutive years of growth
• Neutral Sentiment: Company released the earnings slide deck and hosted an earnings call — useful for investors wanting details on segment trends, pipeline timelines and margin assumptions. MarketBeat — Earnings materials
• Neutral Sentiment: Seeking Alpha published the Q4 earnings call transcript and the results presentation for investors who want full management commentary and Q&A. SA — Earnings call transcript SA — Presentation
• Neutral Sentiment: PR/awareness activity (Will Forte campaign about Huntington’s disease) may raise public awareness but is unlikely to move near‑term fundamentals materially. Yahoo Finance — Will Forte Teams Up with Teva
• Negative Sentiment: FY‑2026 guidance is cautious on revenue: EPS guidance of 2.57–2.77 is roughly in line with consensus, but the revenue range of $16.4–16.8B sits below the ~$17.0B street estimate — investors may view this as a near‑term headwind despite the quarter’s beat.

Analysts Set New Price Targets

TEVA has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Jefferies Financial Group increased their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Scotiabank lifted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday. Barclays initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price objective for the company. Finally, Truist Financial lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $35.67.

Insiders Place Their Bets

In other news, VP Richard Daniell sold 115,468 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. This trade represents a 70.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the sale, the chief accounting officer owned 5,650 shares of the company’s stock, valued at $170,630. This trade represents a 68.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 622,060 shares of company stock worth $17,076,965. 0.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Vontobel Holding Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 5.5% during the second quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock valued at $12,062,000 after buying an additional 37,455 shares during the period. Phoenix Financial Ltd. grew its stake in Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after acquiring an additional 3,533,800 shares during the period. Oak Harvest Investment Services acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $1,010,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 12.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after purchasing an additional 4,306,363 shares during the period. Finally, Swiss National Bank lifted its stake in shares of Teva Pharmaceutical Industries by 15.5% during the 2nd quarter. Swiss National Bank now owns 3,616,500 shares of the company’s stock worth $60,613,000 after purchasing an additional 486,100 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.5%

The firm has a market cap of $37.90 billion, a price-to-earnings ratio of 27.54, a PEG ratio of 1.89 and a beta of 0.66. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The firm has a fifty day moving average price of $30.29 and a 200-day moving average price of $23.03.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.